<DOC>
	<DOCNO>NCT00889057</DOCNO>
	<brief_summary>Aim exploratory phase II study assess clinical activity sorafenib single agent , term percentage patient high grade advance osteosarcoma free progression follow 4 month therapy</brief_summary>
	<brief_title>Sorafenib Relapsed High Grade Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>histologically document surgically resectable metastatic highgrade osteosarcoma progress first second line treatment relapse disease . measurable disease define least one lesion accurately measure mean CT MRI . ECOG PS 0 , 1 estimate life expectancy least 3 month . ECOG P.S . 2 acceptable provide depend solely orthopedic problem Age ≥15 year . Adequate bone marrow , liver renal function Written inform consent Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol . Coexisting malignancy , except basal epithelial cell carcinoma skin solid tumor curatively treat evidence disease ≥3 year . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . History HIV infection chronic hepatitis B C. Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) Patients seizure disorder require medication ( steroids antiepileptic ) Pregnant breastfeed patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial two week completion trial . Patients evidence history bleed diathesis Patients undergoing renal dialysis Patients unable swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>osteosarcoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>target therapy</keyword>
</DOC>